Captor Therapeutics S.A.
CTX | WAR
Overview
Corporate Details
- ISIN(s):
- PLCPTRT00014 (+1 more)
- LEI:
- 259400JHH1S2I2S4O735
- Country:
- Poland
- Address:
- Wrocław Duńska 11, 54-427 Wrocław
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome". Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 14:15 |
Report Publication Announcement
Zmiana terminu publikacji raportu okresowego za pierwsze półrocze 2025 roku - C…
|
Polish | 829 bytes | |
| 2025-08-07 18:23 |
Transaction in Own Shares
Zawarcie umowy nieodpłatnego nabycia akcji własnych przez Spółkę w celu realiza…
|
Polish | 2.2 KB | |
| 2025-07-04 18:22 |
Directors' Dealings
treść powiadomienia
|
Polish | 9.2 KB | |
| 2025-07-04 18:22 |
Directors' Dealings
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Conte…
|
Polish | 702 bytes | |
| 2025-07-02 17:08 |
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających na Zwyczajnym Walnym Zgromadzeniu Spółki 26 c…
|
Polish | 2.0 KB | |
| 2025-06-26 17:18 |
Board/Management Change
oświadczenie
|
Polish | 205.4 KB | |
| 2025-06-26 17:18 |
Proxy Solicitation & Information Statements
życiorys (PL)
|
Polish | 164.7 KB | |
| 2025-06-26 17:18 |
Board/Management Change
życiorys
|
English | 175.3 KB | |
| 2025-06-26 17:18 |
Declaration of Voting Results & Voting Rights Announcements
treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie
|
Polish | 469.4 KB | |
| 2025-06-26 17:18 |
Declaration of Voting Results & Voting Rights Announcements
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie 26 czerwca 2025 r., p…
|
Polish | 1.6 KB | |
| 2025-06-13 18:46 |
Proxy Solicitation & Information Statements
oświadczenie kandydata
|
Polish | 205.4 KB | |
| 2025-06-13 18:46 |
Company Presentation
życiorys zawodowy kandydata_PL (tłumaczenie maszynowe)
|
Polish | 164.7 KB | |
| 2025-06-13 18:46 |
Company Presentation
życiorys zawodowy kandydata
|
English | 175.3 KB | |
| 2025-06-13 18:46 |
Proxy Solicitation & Information Statements
zgłoszenie kandydatury wraz z projektem uchwały
|
Polish | 241.8 KB | |
| 2025-06-13 18:46 |
Board/Management Change
Zgłoszenie kandydata na członka Rady Nadzorczej Spółki - Content (PL)
|
Polish | 1020 bytes |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |